Yoni Freedhoff

Does the new generation of weight-loss drugs mark the end for weight-loss diet researchers, fat-acceptance entrepreneurs, and others? Yoni Freedhoff, MD, thinks it does.

Why Diet Guidelines Matter Even if Zero People Follow Them

Two recent developments may potentially increase GLP-1 coverage for more patients with obesity. The lack of coverage may be another failure of recognizing obesity as a chronic disease.

Recent reports show a decrease in obesity rates; however, a new proposed definition predicts a surge of people with obesity.

Yoni Freedhoff, MD, reviews the new book 'Food Intelligence,' which details the impact of food on nutrition, biochemistry, metabolism, and health.

Many patients inquire about the risk of suicidal ideation with GLP-1s, writes Yoni Freedhoff, MD. Rather than increasing the risk, he has found they actually decrease it.

Cancer prevention guidelines and studies fail to mention weight loss medications and surgeries, and their ability to decrease risk. Is this another form of weight bias?

BMI has come under fire recently as an unreliable marker for diagnosing obesity, but a recent paper contends that BMI is still a valid measurement.

Self-reported diet studies should be evaluated with great skepticism. A better way to evaluate is finding a diet that works for the individual.

Recent research suggests that patients prescribed GLP-1s don’t fill their prescriptions or stop taking them. Yoni Freedhoff, MD, discusses the obstacles to patient adherence.